Nanotechnology: A focus on Treatment of Tuberculosis
Keywords:
Tuberculosis, Nanotechnology, liposome, Polymeric nanoparticle, non-polymeric nanoparticleAbstract
Despite the fact that we live in an era of advanced technology and innovation, infectious diseases, like Tuberculosis (TB), continue to be one of the greatest health challenges worldwide. The main drawbacks of conventional TB treatment are the development of multiple drug resistance, resulting in high dose requirements and subsequent intolerable toxicity. Therefore there is a need of a new system have been receiving special attention with the aim of minimizing the side effects of drug therapy, such as poor bioavailability and the selectivity of drugs. Nanoparticle-based drug delivery systems have considerable potential for treatment of TB. The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. In this review, we discuss the challenges with the current treatment of the disease and shed light on the remarkable potential of nanotechnology to provide more effective treatment and prevention for TB.
References
Kumar Vinay, Abbas AK, Fausto N,
Mitchell RN. Robbins Basic Pathology
,Saunder Elsevier. 2007;8:516–522.
Tuberculosis. The International Union
against Tuberculosis and Lung Disease
(The Union).
http://www.theunion.org/tuberculosis/tuber
culosis.html (accessed February 2008).
Frieden TR, Sterling TR, Munsiff SS, Watt
CJ, Dye C. Tuberculosis (Seminar), Lancet
;362:887–899.
Konstantinos A. "Testing for tuberculosis".
Australian Prescriber, 2010;33:12-18.
Jasmer RM, Nahid P, Hopewell PC
"Clinical practice. Latent tuberculosis
infection".N. Engl. J.
Med.2002;347(23):1860–1866.
"Tuberculosis". World Health Organization.
Retrieved 12 November 2009. Fact
sheet No 104.
World Health Organization
"Epidemiology". Global tuberculosis
control: epidemiology, strategy,
financing.2009:6–33.
Dannenberg AM, Jr. Immunopathogenesis
of pulmonary tuberculosis. Hosp Pract
;28:51–58.
Daniel TM, Bates JH, Downes KA. History
of tuberculosis. In: Bloom BR, editor.
Tuberculosis:Pathogenesis, protection and
control. Washington, DC: ASM Press;
,13–24.
Nardell E. Pathogenesis of tuberculosis. In:
Reichman LB, Herschfield E, editor. Lung
biology in health and disease. New York:
Marcel Dekker, Inc.1993,103–123.
Schmitt E, Meuret G, Stix L. Monocyte
recruitment in tuberculosis and sarcoidosis.
Br J Haematol 1977;35:11–17.
Spencer H. Pathology of the lung, 4th
edition. Vol 1. Oxford: Pergmon Press;
Youmans GP. Tuberculosis. Philadelphia:
The WB Saunders Co; 1979.
Hopewell PC. Overview of clinical
tuberculosis. In: Bloom BR, editor.
Tuberculosis: Pathogenesis, protection and
control. Washington, DC: ASM Press;
pp 25–46.
Yang Z, Kong Y, Wilson F, Foxman B,
Fowler AH, Marrs CF, Cave MD, Bates JH.
Identification of risk factors for
extrapulmonary tuberculosis. Clin Infect
Dis 2004;15, 38(2):199–205.
Gonzalez OY, Adams G, Teeter LD, Bui
TT, Musser JM, Graviss EA. Extrapulmonary manifestations in a large
metropolitan area with a low incidence of
tuberculosis. Int J Tuberc Lung Dis
;7(12):1178–1185.
History of TB. An interesting timeline
available on
http://www.indiachestsociety.org/tb/
timeline.asp/.
Deivanayagam CN. Tuberculosis in the
twenty-first century: The Indian response. J
Indian Med Assoc 2003;101(3):139.
Gandy M, Zumla A. The resurgence of
disease: social and historical perspectives
on the ‘new’ tuberculosis. Soc Sci Med
;55(3):385–401.
Ramachandran R, Balasubramanian R,
Muniyandi M. Socio–economic impact of
TB on patients and families in India. Int J
Tuberc Lung Dis 1999;3:869–877.
Mahadev B, Kumar P. History of
tuberculosis control in Ind. J Indian Med
Assoc 2003;101(3):142–143.
Mitchison DA. Fluoroquinolones in the
treatment of tuberculosis. Am J Respir Crit
Care Med 2004;169:334–335.
Fox W, Sutherland I. A five-year
assessment of patients in a controlled trial
of streptomycin, para-aminosalicylic acid
and streptomycin and para-aminosalicylic
acid. Q J Med 1956;98:221–243.
McDermott W. Antimicrobial therapy of
pulmonary tuberculosis. Bull World Health
Organ 1960;23:427–461.
Hong Kong Chest Service/British Medical
Research Council. Controlled trial of 2, 4
and 6 months of pyrazinamide, in threetimesweekly regimens for smear-positive
pulmonary tuberculosis, including an
assessment of a combined preparation of
isoniazid, rifampin and pyrazinamide. Am
Rev Respir Dis 1991;143:700–706.
World Health Organization. Guidance for
national tuberculosis programmes on the
management of tuberculosis in children.
WHO/HTM/TB/ 2006. 371. Geneva: World
Health Organization, 2006.
Farokhzad OC, Langer R., Impact of
nanotechnology on drug delivery. ACS
Nano. 3(1), 2009,16–20.
Godreuil S, Tazi L, Bañuls AL.
Encyclopedia of infectious diseases:
modern methodologies, in: M. Tibayrenc
(Ed.), Pulmonary Tuberculosis and
Mycobacterium Tuberculosis: Modern
Molecular Epidemiology and Perspectives,
John Wiley & Sons, Hoboken, 2007,1–30.
Aaron L, Saadoun D, Calatroni I, Launay
O, Mémain N, Vincent V et al.
Tuberculosis in HIV-infected patients: a
comprehensive review, Clin. Microbiol.
Infect. 2004;10:388–398.
Dinnes J, Deeks J, Kunst H, Gibson A,
Cummins E, Waugh N et al. A systematic
review of rapid diagnostic tests for the
detection of tuberculosis infection, Health.
Technol. Assess. 2007;11:1–178.
Al-Orainey I. Diagnosis of latent
tuberculosis: can we do better? Ann.
Thorac. Med. 2009;4: 5–9.
Bosman AW, Janssen HM, Meijer EW.
About dendrimers: structure, physical
properties, and applications. Chem Rev
;99:1665–88.
Kumar PV, Asthana A, Dutta T, Jain NK.
Intracellular macrophage uptake of
rifampicin loaded mannosylated
dendrimers, J. Drug Target. 2006;14:546–
Kumar PV, Agashe H, Dutta T, Jain NK.
PEGylated dendritic architecture for
development of a prolonged drug delivery
system of an antitubercular drug, Curr.
Drug Deliv. 2007;4:11–19.
Pitha J, Milecki J, Fales H, Pannell L,
Uekama K. Hydroxypropyl-β-cyclodextrin:
preparation and characterization; effects on
solubility of drugs, International Journal of
Pharmaceutics. 1986;29(1):73-82.
Ferreira DA, Ferreira AG, Vizzotto L,
Federman AN, Gomes A. Analysis of the
molecular association of rifampicin with
hydroxypropyl-β- cyclodextrin, Braz. J.
Pharm. Sci. 2004;1:43–51.
Koester LS, Guterres SS, Roch ML, EiflerLima ML, Zuanazzi JA , Bassani VL.
Ofloxacin/β-Cyclodextrin Complexation,
Drug Development and Industrial Pharmacy
; 27(6):533-540.
Prakash BR,Suresh S, Narendra C.
Balasangameshwer, Physicochemical
characterization of β-cyclodextrin and
hydroxy ethyl β-cyclodextrin complexes of
rifampicina, Ars Pharm. 2006;47:37–59.
Lindenberg M, Kopp S, Dressman JB.
Classification of orally administered drug
on the World Health Organization model
list of essential medicines according to the
Biopharmaceutics Classification System,
Eur. J. Pharm. Biopharm. 2004;58:265–278.
Lenaerts AJ, Gruppo V, Marietta KS,
Johnson CM, Driscoll DK, Tompkins NM.
Preclinical testing of the nitroimidazopyran
PA-824 for activity against Mycobacterium
tuberculosis in a series of in vitro and in
vivo models, Antimicrob. Agents
Chemother. 2005;49: 2294–2301.
Evrard B, Bertholet P, Gueders M, Flament
MP, Piel G, Delattre L.Cyclodextrins as a
potential carrier in drug nebulization, J.
Control. Release 2004;96:403–410.
Kataoka K, Harada A, Nagasaki Y. Block
copolymer micelles for drug delivery:
design, characterization and biological
significance, Adv. Drug Deliv. Rev.
;47:113–131.
Croy SR, Kwon GS. Polymeric micelles for
drug delivery, Curr. Pharm. Des.
;12:4669–4684.
Chiappetta DA, Sosnik A. Poly(ethylene
oxide)–poly(propylene oxide) block
copolymer micelles as drug delivery agents:
Improved hydrosolubility, stability and
bioavailability of drugs, Eur. J. Pharm.
Biopharm. 2007;66:303–317.
Moretton MA, Glisoni RJ, Chiappetta DA,
Sosnik A. Synthesis and characterization of
amphiphilic poly/epsilon-caprolactone)-
poly (ethyleneglycol) block copolymers.
Silva M, Ricelli NL, El OS, Valentim CS,
Ferreira AG, Sato DN.Potential
tuberculostatic agent: micelle-forming
pyrazinamide prodrug, Arch. Pharm. Chem.
Life Sci. 2006;339:283–290.
Silva M, Ferreira EI, Leite CQF, Sato DN.
Preparation of polymeric micelles for use as
carriers of tuberculostatic drugs, Trop. J.
Pharm. Res.2007;6:815–824.
Jin Y, Chen S, Xin R, Zhou Y. Monolayers
of the lipid derivatives of isoniazid atbthe
air/water interface and the formation of
self-assembled nanostructures in water,
Colloids Surf., B Biointerfaces
;64:229–235.
Soppimath KS, Aminabhavi TM, Kulkarni
AR, Rudzinski WE. Biodegradable
polymeric nanoparticles as drug delivery
devices, J. Control. Release 2001;70:1–20.
Delie F, Blanco-Prieto MJ. Polymeric
particulates to improve oral bioavailability
of peptide drugs, Molecules 2005;10:65–80.
Brannon-Peppas L. Recent advances on the
use of biodegradable microparticles and
nanoparticles in controlled drug delivery,
Int. J. Pharm.1995;116:1–9.
Owens TE , Peppas NA. Opsonization,
biodistribution, and pharmacokinetics of
polymeric nanoparticles, Int. J. Pharm.
;307:93–102.
Anisimova YV, Gelperina SI, Peloquin
CA, Heifets LB. Nanoparticles as
antituberculosis drugs carriers: effect on
activity against My cobacterium
tuberculosis in human monocyte-derived
macrophages, J. Nanopart. Res. 2000;
:165–171.
Kisich KO, Gelperina SI, Higgins MP,
Wilson S, Shipulo E, Oganesyan E.
Encapsulation of moxifloxacin within
poly(butyl cyanoacrylate) nanoparticles
enhances efficacy against intracellular
Mycobacterium tuberculosis, Int. J. Pharm.
;345:154–162.
Shipulo EV, Lyubimov II, Maksimenko
OO, Vanchugova LV, Oganesyan EA,
Sveshnikov PG. Development of a
nanosomal formulation of moxifloxacin
based on poly (butyl-2-cyanoacrylate),
Pharm. Chem. J. 2008;42:145–149.
Pandey R, Zahoor A, Sharma S, Khuller
GK. Nanoparticle encapsulated
antitubercular drugs as a potential oral drug
delivery system against murine
tuberculosis, Tuberculosis 2003;83:373–
Zahoor A, Pandey R, Sharma S, Khuller
GK. Pharmacokinetic and
pharmacodynamic behavior of
antitubercular drugs encapsulated in
alginate nanoparticles at two doses, Int. J.
Antimicrob. Agents 2006;27:409–416.
Gregoriadis G, Wills EJ, Swain CP, Tavill
AS. Drug carrier potential of liposomes in
cancer chemotherapy, Lancet 1974;1:1313–
Klemens SP, Cynamon MH, Swenson CE,
Ginsberg RS. Liposome-encapsulatedgentamicin therapy of Mycobacterium
avium complex infection in beige mice,
Antimicrob. Agents Chemother.
;34:967–970.
Leitzke S, Bucke W, Borner K, Muller R,
Hahn H, Ehlers S. Rationale for and
efficacy of prolonged-interval treatment
using liposome-encapsulated amikacin in
experimental Mycobacterium avium
infection, Antimicrob. Agents Chemother.
;42: 459–461.
Oh YK, Nix DE, Straubinger RM.
Formulation and efficacy of
liposomeencapsulated antibiotics for
therapy of intracellular Mycobacterium
avium infection, Antimicrob. Agents
Chemother. 1995;39:2104–2111.
Duzgunes N, Flasher D, Reddy MV, LunaHerrera J, Gangadharam PR. Treatment of
intracellular Mycobacterium avium
complex infection by free and
liposomeencapsulated sparfloxacin,
Antimicrob. Agents Chemother.
;40:2618–2621.
Deol P, Khuller GK. Lung specific
liposomes: stability, biodistribution and
toxicity of liposomal antitubercular drugs in
mice, Biochem. Biophys. Acta
;1334:161–172.
Deol P, Khuller GK, Joshi K. Therapeutic
efficacies of isoniazid and rifampin
encapsulated in lung-specific stealth
liposomes against Mycobacterium
tuberculosis infection induced in mice,
Antimicrob. Agents Chemother.
;41:1211–1214.
Mehta RT, Keyhani A, McQueen TJ,
Rosenbaum B, Rolston KV, Tarrand JJ. In
vitro activities of free and liposomal drugs
against Mycobacterium avium– M.
intracellulare complex and Mycobacterium
tuberculosis, Antimicrob. Agents
Chemother. 1999;37:2584–2587.
Adams LB, Sinha I, Franzblau SG,
Krahenbuhl LJ, Mehta RT. Effective
treatment of acute and chronic murine
tuberculosis with liposome-encapsulated
clofazimine, Antimicrob. Agents
Chemother. 1999;43:1638–1643.
